Potential of the right ventricular endomyocardial biopsy to diagnose and assist in the management of congestive heart failure: insights from recent clinical trials.

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In the United States congestive heart failure is most commonly due to ischemic cardiomyopathy, but nonischemic causes of cardiomyopathy can also result in congestive heart failure. Indeed, nonischemic dilated cardiomyopathy affects approximately 100,000 persons in the United States and is responsible for 45% of heart transplants. Although these patients undergo thorough cardiovascular evaluation, a specific cause is usually not found. Endomyocardial biopsy may yield diagnostic and prognostic information in this setting, and there has been a renewed interest in the use of endomyocardial biopsy in the evaluation of specific subsets of patients with congestive heart failure to identify potentially treatable myocarditides. However, the role of endomyocardial biopsy in the evaluation of patients with nonischemic cardiomyopathy is ill defined. In this review, the authors discuss the latest data on the risks and the utility of endomyocardial biopsy in the management of heart failure in the setting of dilated cardiomyopathy and specific myocarditides. Gaps in present knowledge and the obstacles to research in this area are identified.

Original languageEnglish (US)
Pages (from-to)133-139
Number of pages7
JournalCongestive heart failure (Greenwich, Conn.)
Volume10
Issue number3
StatePublished - May 2004

Fingerprint

Heart Failure
Cardiomyopathies
Clinical Trials
Biopsy
Dilated Cardiomyopathy
Transplants
Research

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{1a98cd4757a9411bb76b3f8b143ee09b,
title = "Potential of the right ventricular endomyocardial biopsy to diagnose and assist in the management of congestive heart failure: insights from recent clinical trials.",
abstract = "In the United States congestive heart failure is most commonly due to ischemic cardiomyopathy, but nonischemic causes of cardiomyopathy can also result in congestive heart failure. Indeed, nonischemic dilated cardiomyopathy affects approximately 100,000 persons in the United States and is responsible for 45{\%} of heart transplants. Although these patients undergo thorough cardiovascular evaluation, a specific cause is usually not found. Endomyocardial biopsy may yield diagnostic and prognostic information in this setting, and there has been a renewed interest in the use of endomyocardial biopsy in the evaluation of specific subsets of patients with congestive heart failure to identify potentially treatable myocarditides. However, the role of endomyocardial biopsy in the evaluation of patients with nonischemic cardiomyopathy is ill defined. In this review, the authors discuss the latest data on the risks and the utility of endomyocardial biopsy in the management of heart failure in the setting of dilated cardiomyopathy and specific myocarditides. Gaps in present knowledge and the obstacles to research in this area are identified.",
author = "Lambert Wu and Cooper, {Leslie T Jr.}",
year = "2004",
month = "5",
language = "English (US)",
volume = "10",
pages = "133--139",
journal = "Prevention and Management of Congestive Heart Failure",
issn = "1079-7998",
publisher = "Le Jacq Communications, Inc.",
number = "3",

}

TY - JOUR

T1 - Potential of the right ventricular endomyocardial biopsy to diagnose and assist in the management of congestive heart failure

T2 - insights from recent clinical trials.

AU - Wu, Lambert

AU - Cooper, Leslie T Jr.

PY - 2004/5

Y1 - 2004/5

N2 - In the United States congestive heart failure is most commonly due to ischemic cardiomyopathy, but nonischemic causes of cardiomyopathy can also result in congestive heart failure. Indeed, nonischemic dilated cardiomyopathy affects approximately 100,000 persons in the United States and is responsible for 45% of heart transplants. Although these patients undergo thorough cardiovascular evaluation, a specific cause is usually not found. Endomyocardial biopsy may yield diagnostic and prognostic information in this setting, and there has been a renewed interest in the use of endomyocardial biopsy in the evaluation of specific subsets of patients with congestive heart failure to identify potentially treatable myocarditides. However, the role of endomyocardial biopsy in the evaluation of patients with nonischemic cardiomyopathy is ill defined. In this review, the authors discuss the latest data on the risks and the utility of endomyocardial biopsy in the management of heart failure in the setting of dilated cardiomyopathy and specific myocarditides. Gaps in present knowledge and the obstacles to research in this area are identified.

AB - In the United States congestive heart failure is most commonly due to ischemic cardiomyopathy, but nonischemic causes of cardiomyopathy can also result in congestive heart failure. Indeed, nonischemic dilated cardiomyopathy affects approximately 100,000 persons in the United States and is responsible for 45% of heart transplants. Although these patients undergo thorough cardiovascular evaluation, a specific cause is usually not found. Endomyocardial biopsy may yield diagnostic and prognostic information in this setting, and there has been a renewed interest in the use of endomyocardial biopsy in the evaluation of specific subsets of patients with congestive heart failure to identify potentially treatable myocarditides. However, the role of endomyocardial biopsy in the evaluation of patients with nonischemic cardiomyopathy is ill defined. In this review, the authors discuss the latest data on the risks and the utility of endomyocardial biopsy in the management of heart failure in the setting of dilated cardiomyopathy and specific myocarditides. Gaps in present knowledge and the obstacles to research in this area are identified.

UR - http://www.scopus.com/inward/record.url?scp=4344691960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344691960&partnerID=8YFLogxK

M3 - Article

C2 - 15184727

AN - SCOPUS:4344691960

VL - 10

SP - 133

EP - 139

JO - Prevention and Management of Congestive Heart Failure

JF - Prevention and Management of Congestive Heart Failure

SN - 1079-7998

IS - 3

ER -